Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod in moderate Alzheimer's disease
NCT06862960Phase 2Recruiting
- Sponsor
- Chen Xiao Chun
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ozanimod in Alzheimer's disease (AD), sponsored by Chen Xiao Chun. Started Aug 2025; status: recruiting.
02
Drugs
ozanimod
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06862960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06862960.